Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Freedom Holdings Signs Definitive Agreement with MEDcann Industries, Inc.

FREEDOM HLDG INC.

MCapMediaWire -- Freedom Holdings, Inc. (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce that it has entered into a Definitive Agreement that will change the control and operations of the Company to MEDcann Industries, Inc. MEDcann is going to modify the forward direction of Freedom to include topical and organic natural Marijuana plant-based products (OTC) “over the counter” entering the Cannabis health care products market in which the Company management believes will boost shareholder value. Freedom Holdings management will bring the companies platforms to a new level to be current with all SEC, OTC and FINRA requirements, publishing its 2022-year end Information and Statements to bring the company current and re-structuring the company with a productive reorganization. The will allow the Company to negotiate with private companies in the Cannabis industry specifically looking for beverage, cosmetics, vitamin, and medicinal companies to acquire and or joint venture with. Under the terms of the agreement, MEDcann is to purchase 40,000,000 restricted shares from the Company for $50,000.00 (.00125 per share) representing the 80% ownership of the Company and Brian Kistler shall resign all Officer/Director positions only to serve as an advisor for a period of 2 years to insure a smooth transition and John Vivian, CEO of MEDcann shall simultaneously be appointed as the Chairman and CEO of Freedom and MEDcann as the parent company shall assume the debt and ongoing operational costs of Freedom All financial disclosures are to be brought current The Closing of the conditions as outlined, Freedom has become a majority owned subsidiary of MEDcann with operations of MEDcann Industries to be transferred into Freedom for future development. About MEDcann Industries, Inc. MEDcann Industries, Inc. was founded in Februsry 2020 to create and develop a high-quality worldwide Distribution, Research and Manufacturing Facility. Investigating the resources, we found many different types of products and plan to be one of the competitive manufactures and marketers. We intend to manufacture and assemble everything from Medicine, Cosmetic to Health treatment products and drinks. For more information regarding MEDcann please visit https://MEDcannindustries.com/ Press Release Contact: Brian Kistler CEO Freedom Holdings, Inc. 260-490-9990 John Vivian CEO MEDcann Industries, Inc 813-699-4098 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. Brian Kistler +1 260-490-9990 MEDcann Industries, Inc John Vivian +1 813-699-4098

January 26, 2023 01:28 PM Eastern Standard Time

A Turning Point In Vietnam’s HealthTech: VinBrain Announces Collaboration with Microsoft To Expand AI-Powered Healthcare to Patients Worldwide

Vingroup

VinBrain will collaborate with Microsoft in data sharing, product cross-validation, and product research & development. VinBrain is the first Vietnamese customer to sign a formal collaboration agreement with Microsoft to develop AI-powered healthcare services HANOI, VIETNAM - Media OutReach - 26 January 2023 - VinBrain, one of Vietnam’s leading technology companies, is working to transform global healthcare through its AI products. One of VinBrain’s primary products is DrAid™, an AI pathology prediction platform that has demonstrated its usefulness in over 150 hospitals and earned a prestige ACM SIGAI Industry Award 2021. DrAid™ is a value-added use case for Microsoft to collaborate on the validation of the impact of Florence, a new foundation model for computer vision developed by Microsoft. In addition, DrAid™ is the first and only AI software for X-ray Diagnostics in Southeast Asia to be cleared by The United States Food and Drug Administration (FDA), putting Vietnam on the map of 6 countries owning an FDA-cleared AI product for Chest X-ray Pneumothorax finding. Microsoft will bring trusted and integrated cloud capabilities to VinBrain’s developers, enabling VinBrain to deliver a better experience for users. This collaboration will implement data sharing through Microsoft Azure and apply it to the data gathered by VinBrain’s DrAid™. Microsoft will also help safeguard sensitive patient data, further enhancing the security and privacy of VinBrain’s offering, to manage ever-changing compliance regulations and improve data governance and trust. DrAid™ currently has a large dataset that has been collected from multiple sources: USA, Europe, and Asia that complies of 2,300,000+ images, of which ~400,000 are labeled images approved by senior radiologists. Beside this data sharing, VinBrain will also offer the field of medical image data annotation services where VinBrain can utilize a pool of top doctors, including pathologists, radiologists, etc., and early field validation to developed AI to 100+ hospital-based customers. "Nearly 2,000 doctors are currently using DrAid™ at more than 100 hospitals across Vietnam, including those with the largest patient traffic, such as 108 Military Central Hospital, 199 Hospital, Vietnam National Cancer Hospital, etc. Therefore, our datasets are updated and enlarged on a daily basis, which benefits the progress of data assessment", said Mr. Steven Truong, VinBrain's CEO. “Using the latest foundation of AI technology and evaluation, this collaboration with Microsoft will directly impact billions of people through early detection and workflow productivity.” With Cross-Validation, VinBrain will check the Deep Learning models and analyze AI-powered worldwide health outcomes using the latest and evolving technology along with Azure Cognitive Services for Vision. The remarkable capability evaluation period of Azure AI, such as computer vision and the latest Florence foundation model, will be directly empowering VinBrain and other HealthTech companies to improve productivity and efficiency, leading to faster time to market and a potential high R&D cost saving especially for the HealthTech space. With the help of these technologies, the VinBrain developer team can also access and develop AI capabilities for processing uploaded images and returning information and building, deploying, and improving image classifiers. This will accordingly increase the accuracy rate of medical imaging for DrAid™. With Product Research and Development (R&D), VinBrain will work with Microsoft to take advantage of Azure Cognitive Services to overcome global healthcare obstacles. DrAid™ is professionally consulted by hundreds of specialized doctors in the progress of development and regular quality checking. A future for sustainable healthcare service The COVID-19 pandemic has affected every aspect of the healthcare system, interfering with the continuity of healthcare delivery practices and patient access to high-quality medical care. Additionally, DrAid™ has also been added to the portfolio of Ferrum, the U.S.'s leading artificial intelligence marketplace, in the category of AI-based products for radiology to help deliver the highest quality patient care. Both teams are committed to providing trusted and reliable solutions for some of the most pressing healthcare challenges using technology innovation with advanced data and analytics capabilities. On the social aspect, this will help speed up the process of resolving an increasing number of healthcare issues with a lack of infrastructure, uneven doctor-to-patient ratio, and increased demand for healthcare services. DrAid™ has also affirmed its impact during COVID-19, for it has increased the accuracy and productivity of medical examination and treatment for doctors and offered high-quality medical services for numerous citizens regardless of region and economic conditions. With the help of Microsoft Azure technology, VinBrain can apply AI to improve medical services in remote areas, especially those with limited medical facilities, thereby ensuring healthcare is delivered impartially; this is also aligned with the Corporate Social Responsibility of both companies. “We take pride in our relationship with Microsoft, as it deepens our focus on the HealthTech industry and accelerates the growth of our products with the best tech and business resources. The collaboration will also enable us to fulfill Vietnam’s potential for innovation on an international scale and show our trust in the future of AI-powered products”, Mr. Steven Truong, CEO of VinBrain emphasized. "At Microsoft, we have prioritized our investment in the healthcare industry to address the most prevalent and persistent health and business challenges. The collaboration with VinBrain will be a good start for us to enlarge the sphere of operation in healthcare in Southeast Asia," said Dr. Yumao Lu, Partner Engineering Manager of Microsoft USA. About VinBrain: VinBrain is a leading AI healthcare products company, funded by Vingroup, the largest conglomerate by market capitalization in Việt Nam. Its mission is to infuse AI and IoT to improve people’s lives and productivity.To learn more, visit VinBrain’s website: https://vinbrain.net/ Contact Details VinBrain JSC info@vinbrain.net

January 26, 2023 11:15 AM Eastern Standard Time

Image

Part 4 of Legal & General’s new study on the U.S. Gig Economy finds workers lacking health insurance coverage and other financial safety nets

Legal & General

- 23% of respondents have no health insurance - 1 in 3 gig working parents have no health insurance - 40% of gig workers have life insurance, including those with partners and children - 42% ranked access to healthcare, life insurance, and a pension plan as top lures back to traditional employment A fourth segment of a broad new study sponsored by Legal & General Group ( LGEN, LGNNY ), U.S. Gig Economy, Part 4: Gig Workers Aren’t Meeting Their Health, Life Insurance Needs, was released today. The report is part of a continuing exploration of the changing nature of work in the U.S., people’s relationship to it, and what employers should be thinking about in order to attract back talent. The study looks into why people choose or find their way to the U.S. Gig Economy, and some of the tradeoffs they make to maintain their independence. Between Part 3, Why Gig Work Is Becoming a Choice for So Many, and the current report, Legal & General released a Flash Report on Tech Workers in the U.S. Gig Economy in response to massive layoffs in the tech sector and the flood of workers likely to enter the freelance market as a result. This fourth segment of the data-rich study, Gig Workers Aren’t Meeting Their Health, Life Insurance Needs, finds that nearly half (48%) of gig workers find their access to health insurance negatively affected by deciding to engage in freelance work. The study also looks into the proportion and demographics of gig workers who are underinsured or uninsured for both health and life insurance and seeks to answer the question of how their situation compares to salaried American workers. The study found that many gig workers are stressed and frustrated by the lack of a social safety net, with the discrepancy between the overall number of Americans insured for healthcare and the number of gig workers insured pointing to a financially insecure and underrepresented segment of the workforce. Nor were the shortfalls limited to health insurance. Other key social and financial safety nets were also poorly represented among gig workers, the study notes, including life insurance, disability insurance, and retirement savings. “The pandemic has made it abundantly clear that we can’t have economic health without physical health. Healthcare coverage is considered a given in most wealthy, industrialized nations. American gig workers expressing insecurity over their coverage acts as a call to action for companies to tackle this deeply ingrained divide. The private sector has the collective know-how and financial wherewithal to develop creative levelling-up solutions that make both social and fiscal sense.” Sir Nigel Wilson, Chief Executive, Legal & General Group Other factors contribute to low insurance coverage Legal & General’s study looks at the complex and multifaceted societal and financial factors behind independent work, including the role of the pandemic in worsening medical care and coverage for many gig workers, and the implications of recent U.S. government policy changes. “The steady growth of the U.S. gig economy spotlights the importance of addressing these basic safety nets. While a handful of gig work platforms are doing a great job of providing affordable coverage, the larger population of independent workers has yet to be included. We hope this research will bring to the forefront the need to create a user-friendly benefits infrastructure and bring it to this broader population of gig workers.” John Godfrey, Director of Levelling-Up, Legal & General Group Future segments of this research will look in depth at the fierce independent mindedness of gig workers; their outlook and situation around retirement planning; what it would take to get gig workers to go back to the traditional workplace; and a closer look at the pandemic fallout for gig workers. To receive a pdf of any of these reports, please email Meir Kahtan/MKPR at mkahtan@rcn.com. Notes to editors The information contained in this press release is intended solely for journalists and should not be relied upon by private investors or any other persons to make financial decisions About the Study Legal & General undertook proprietary research into the attitudes and changes U.S. gig workers are experiencing in relation to their work situations and financial outlook. The U.S. Gig Economy research was compiled using original survey data from 1044 U.S.-based workers aged 18 to 60 who are neither students nor retired, and who earn at least 60% of their income from gig work. The data was collected via online survey fielded to individuals sample sourced from YouGov’s US panel. The Legal & General-designed survey was scripted and hosted on Gryphon, YouGov’s proprietary survey scripting platform, and the field work took place between August 19 and 31, 2022. Key demographics such as age, gender and region were allowed to fall out naturally. 20 questions were designed to understand facts about earnings, drivers of and barriers to gig working, financial product ownership & financial capacity when coming across adverse situations, and future expectations of being involved in the gig economy. Verbatim comments were captured by Legal & General in research carried out in June 2022. Established in 1836, Legal & General is one of the UK's leading financial services groups and a major global investor, with over £1.4 trillion ($1.7 trillion) in total assets under management* of which a third is international. We also provide powerful asset origination capabilities. Together, these underpin our leading retirement and protection solutions: we are a leading international player in pension risk transfer, in UK and US life insurance, and in UK workplace pensions and retirement income. Through inclusive capitalism, we aim to build a better society by investing in long-term assets that benefit everyone. *as of December 31, 2021 Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.legalandgeneralgroup.com/

January 26, 2023 10:35 AM Eastern Standard Time

CeCors Finalizes Terms with VetComm to Enter the Multi-Billion Dollar Veteran Benefits Industry

CeCors, Inc.

McapMediaWire - CECORS, INC. (OTC: CEOS ) ("CeCors" or the "Company"), is pleased to provide corporate highlights from the final quarter of fiscal 2022 and an update to the earlier press release dated December 19, 2022, regarding initial negotiations with VetComm Corp. CeCors and VetComm founder, Kate Monroe have agreed in principle to terms as part of the planned 100 percent purchase of VetComm Corp. VetComm Corp. is a veteran's education, and benefits company focused on assisting the over 14 million United States veterans that qualify for underutilized annual benefits and owed compensation, resulting in estimated Billions of dollars of unclaimed benefits every month in the United States. Users of VetComm can file claims for free, with no medical or service records required. VetComm also focuses resources to support and donate to Veteran Charities. VetComm's goal for 2023 is to help 1 million veterans get rated, offering support packages leading to benefits with costs ranging from $247 to $997, generating potential revenues for VetComm between $247 million and $997 million annually. As part of the initially agreed-upon terms of the acquisition, CeCors will issue a combination of unregistered, restricted preferred and common shares. In addition, each of Sukhinder Kalsi, Director and CFO and Amar Bhatal, President, Secretary and Director, will assign half of their Series A Preferred Shares to VetComm founder Kate Monroe as part of the proposed acquisition terms. Management of the Company continues to be focused on limiting dilution and bringing value to shareholders using CeCors current capital structure. Concurrent with closing, Kate Monroe will step in as CEO of CeCors, Inc., and VetComm will operate as a wholly-owned subsidiary. Operations of the controlled subsidiary PsyKey, Inc. will continue to run in parallel. "Now that we have come to a mutual agreement on the terms of the acquisition, we can focus on closing and consolidating our efforts moving forward. We have worked diligently to reach terms agreeable to all parties and expect to close the transaction in Q1 2023. The more we learned about VetComm as part of our due diligence process, the more we understood VetComm's vast potential for growth. Kate is determined to enroll 1 million veterans into the VetComm platform this fiscal year (2023), potentially putting billions of dollars into the pockets of deserving veterans who have put their lives on the line for their country." commented Mr. Sukhinder Kalsi, CeCors' Chief Financial Officer. Mr. Kalsi added, "Kate is the most determined and motivated individual I've ever encountered. Being a marine corps veteran, she has real insight into the daily challenges veterans face due to a lack of financial and mental health resources. With the current uncertainty in the global economy, VetComm can be an indispensable service partner for all vets seeking benefits." "I'm very excited to have come to terms on the acquisition of VetComm. We have an opportunity to get our message out to every veteran who is entitled to unused benefits and compensation. The idea of being involved with a public company only enhances our platform to get our message out to the over 14 million veterans who are entitled to compensation. With our existing high-level political and celebrity backing, we're confident we will hit our goal of enrolling 1 million veterans this year," concluded Kate Monroe. Year in Review for CeCors, Inc. 2022 Milestones The Company has worked diligently over the past year to acquire its initial revenue-generating operations, and OTCMarkets has recently updated our online profile to denote our exit from Shell Status. This milestone was in part achieved as a result of the successful launch of our first retail-ready product offering, PsyKey Functional Mushroom Infused Coffee. The launch saw both consumer support and major corporate interest leading to the fulfillment of substantial purchase orders. Continuing with management's goal of steady corporate growth and wanting to help create inclusivity and ease of access to mental health support, the Company also recently completed the development of its Telemental Health App PsyKey Live. The App is currently being beta tested with real-world scenarios and expanded to allow for additional capabilities. Building a strong medical, scientific, and management team also continues to be a priority for the Company and was complemented by the 2022 additions of John Gustin as head of Global Business Development; Dr. Michael J. McCarthy as an appointee to our Scientific Advisory Board; and Dr. Shahiem Hartley to our Medical Advisory Board. The addition of Dr. Hartley will help the Company build a mental health support and education platform, while the additions of John Gustin and Dr. McCarthy provide a conduit into the scientific world and the ability for the Company to adequately develop and introduce scientific advancements and patented technologies to the market. On behalf of the entire CeCors and PsyKey team, we would like to express our deepest gratitude to our amazing shareholders for their patience and support this past year. We are excited about what 2023 has in store for the Company, and we look forward to providing regular updates as we continue. For further information: Publicly traded company (OTC: CEOS) Website: www.psykeyworld.com E-mail: info@psykeyworld.com Follow us on Twitter: https://twitter.com/PsyKeyworld Forward-Looking Statements: Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements. Contact Details Sukhinderpaul Kalsi info@psykeyworld.com Company Website https://psykeyworld.com/

January 26, 2023 09:45 AM Eastern Standard Time

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

BioRestorative Therapies, Inc.

By Faith Ashmore, Benzinga BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. The company is engaged in developing therapeutic products using cell and tissue protocols, primarily with adult stem cells, for large multi-billion dollar markets that are underserved and affect millions of Americans, like chronic lower back pain and metabolic disorders. BioRestorative currently has two major programs that are being evaluated for a variety of chronic diseases and pain. Their novel drug BRTX-100 is an autologous stem cell product; the cells are harvested, cultured and then injected directly into the patient’s body. BioRestorative’s other product — ThermoStem® — has shown promising results in preclinical models for the treatment of obesity and related metabolic diseases. In December, BioRestorative was awarded a Small Business Innovation Research (SBIR) grant. This grant was given for the development and evaluation of the company’s ThermoStem program for developing a therapeutic to treat polycystic ovary syndrome (PCOS). Previously, the company was granted a Small Business Technology Transfer (STTR) grant for Phase 1 development of BRTX-100 to explore the therapeutic effects of PEG-peptide hydrogel-encapsulated hypoxic bone marrow stem cells. It’s rare that a company of its size has received two government grants, validating its technology and potential application. The company entered into an agreement with Regenexx, LLC, providing BioRestorative with the exclusive worldwide commercial rights of the intellectual property that is underlying some key principles of BRTX-100. Currently, BRTX-100 is in a Phase 2 trial with approximately 15 sites in the U.S. This exclusive arrangement should provide value to BRTX and or a commercial partner in potential later-stage development transactions. BRTX-100 began Phase 2 trials in February, defined as a prospective, randomized, double-blinded controlled study to evaluate the efficacy and safety of BRTX from a single injected dose. One of the company’s significant developments in 2022 was the completion of a cGMP manufacturing facility with an ISO 7-certified clean room. This facility was completed in April and was instrumental in progressing the company forward to meet the needs of Phase 2 clinical trials for chronic lumbar disc disease. Throughout the year, BioRestorative participated in several high-profile conferences. The company presented at H.C. Wainwright Bioconnect, Roth Inaugural Healthcare Conference and Dawson James Securities Conference, to name a few. BioRestorative was also granted a patent application for their ThermoStem program in Japan, which demonstrates the company’s potential for global application of their therapeutic products. BioRestorative and other companies like Lineage Cell Therapeutics Inc (NYSE: LCTX), Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI), Vericel Corp (NASDAQ: VCEL) and large cap pharma as well such as Novo Nordisk (NYSE: NVO) and Pfizer Inc. (NYSE: PFE) are leading the charge towards a new era of medical advancement. As biotech companies become increasingly successful at providing therapeutic solutions, it will be interesting to see how technology and innovation leads to higher quality of life for patients who have previously been left with little or no solutions. To learn more about BioRestorative, visit its website. This article was originally published on Benzinga here. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

January 26, 2023 08:30 AM Eastern Standard Time

1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition

1606 Corp

McapMediaWire -- 1606 Corp (OTC: CBDW ), an acquisition-based CBD product distribution company, announced that the company has successfully started trading on the OTC Market under the Ticker Symbol of CBDW. 1606 Corp’s S-1 registration statement became effective on January 22, 2022 and began trading on the OTC Market on January 17th, 2023. CBDW is a ticker symbol that embodies the business model of 1606 Corp and highlights management's goal to build a product-driven CBD-Wellness company. CBD.Inc and 1606 Corp. look to accumulate a diverse portfolio of CBD products and companies nationwide. The business model will achieve management goals by consolidating the fragmented CBD industry via acquisitions. The Ticker symbol CBDW will provide market recognition of these goals and the company's business model. "It’s always been a critical component of trading on the public markets for companies to utilize a stock symbol that reinforces the mission of the company. We purposefully requested the ticker symbol "CBDW" because that ticker represents us as a business. Our core focus is on buying companies with great wellness products and brands that embody the benefits of CBD, and the ticker says all of that in just four letters." said Greg Lambrecht, CEO, and Chairman of 1606 Corp. 1606 Corp (OTC: CBDW) has signed a letter of intent (LOI) to purchase 51% of Brio Nutrition’s ( https://brionutrition.com / ), a profitable CBD development and distribution company. Brio Nutrition's has agreed to an LOI with 1606 Corp and filed for an audit on September 30th, 2022, which is still pending. Upon completion of the audit, a combination of stock and cash, totaling USD 600,000.00, will be transferred, and the transaction will be complete. Brio Nutrition Revenue (unaudited) 2021 $763,079 2020 $1,116,336 "Brio Nutrition's is the first of many acquisitions we intend on closing this year. The CBD market is quite fragmented and growing so we're on a mission to consolidate the industry by purchasing companies with strong product brands and established distribution. We'll use these accumulated outlets to cross-pollinate our product line. It's going to be the key to our success" Said Greg Lambrecht CEO of 1606 Corp DBA CBD Inc. About Brio Nutrition; Brio Nutrition is a premium CBD product developer, supplier, and wellness company focused on providing the highest quality hemp derivatives and formulations for people and pets. Brio Nutrition develops and supplies CBD gummies, topicals, capsules, topicals and oils to assist.in treating pain, anxiety, sleep performance, and depression for all those in need. The products developed and distributed by Brio provide holistic solutions designed to ensure a higher quality of life for all living beings. About 1606 Corporation Management; Greg Lambrecht has successfully taken three companies public. He is starting with premium cigars International which went to the NASDAQ in 1997. Again in 2011, Mr. Lambrecht took Singlepoint public on the OTC Markets. Singlepoint is pursuing a move up the NASDAQ as well. He will take the knowledge and expertise learned in both these endeavors into the new public entity 1606 Corp. About 1606 Corp; In April 2021, 1606 Corp. was spun off from Singlepoint Inc. (OTCQB: SING).1606 has been able to develop smokable hemp brands to add to 1606 original, including Truz and CBD Singlez ( www.1606hemp.com ) The company intends to acquire Companies in the CBD, including brands, distribution, retail outlets, and manufacturing. 1606 Corp. was awarded the ticker symbol CBDW on January 12th, 2022. Industry Information; The Cannabidiol (CBD) market accounted for USD 12.8 billion in 2021 and is estimated to grow with a 21.7% CAGR between 2022 and 2028, according to Grand view research (link). The global cannabidiol (CBD) market size was valued at $5.18 billion in 2021 and is expected to expand, at a compounded annual growth rate (CAGR) of 16.8% from 2022 to 2030. Cannabidiol (CBD) is a chemical compound that is found in the cannabis Sativa plant, and is extracted from hemp or cannabis, generally from hemp due to its naturally high cannabidiol (CBD) content.. Forward-Looking Statements This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of 1606 Corp (the "Company"), its directors, or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the Company's control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Contact: Greg Lambrecht greg@1606corp.com CBD.inc Austen Lambrecht austen@1606corp.com CBD.inc 888-223-9510 Company Websites; www.1606hemp.com www.CBD.Inc Contact Details Greg Lambrecht greg@1606corp.com Austen Lambrecht austen@1606corp.com

January 26, 2023 08:00 AM Eastern Standard Time

Spectral MD "very excited" about 2023

Spectral MD Holdings Ltd

Spectral MD Holdings Ltd (AIM:SMD) chief operating officer Niko Pagoulatos speaks to Proactive's Thomas Warner about his plans for the company during 2023. He reveals more details about the timeline for the DeepView Wound Imaging System and explains what milestones investors can expect, adding that he is "very excited" about what the year has in store. Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video

Oxford Cannabinoid Technologies with "lots to look forward to" after interims

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker speaks to Proactive's Thomas Warner following the release of interim results for the six months ending 31st October 2022. Sowemimo-Coker looks ahead to what investors can expect during the first half, saying that there is "plenty to look forward to." She also reveals details of the current state of the company's finances. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video

Roquefort Therapeutics demonstrates initial safety in two antibody programmes

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) CEO Ajan Reginald speaks to Proactive's Thomas Warner after announcing that the company's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programmes have successfully demonstrated safety in pre-clinical studies. Reginald says that he's now hoping to "move rapidly into efficacy testing". Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video

1 ... 169 170 171 172 173 ... 308